Hemolysis (direct & indirect)
1. Biological Effect: Hemocompatibility Tests
2. Turnaround time: 6 weeks
3. Sample Requirements:
ISO
120 cm² (test item < 0.5 mm thick);
60 cm² (test item ≥ 0.5 mm thick);
4 grams;
20 ml;
at least 6 test items;
ISO 10993-4
The purpose of the study is to determine the potential hemolytic activity of the medical device and its extract on human blood. The test item is tested in parallel in an indirect (extract in CMF-PBS) and a direct way (medical device). After exposition of the blood to the device, the hemolytic effect is assessed by the amount of free hemoglobin in the sample.
How We Work
Discovery & Insight
We begin with an in-depth consultation to understand your needs, challenges, and objectives. This helps us define the right strategy and scientific approach for your project.
Design & Development
Our experts translate your vision into actionable plans — combining innovative research, data, and technology to build precise and reliable solutions.
Delivery & Support
We implement the solution with full transparency and ongoing communication. After delivery, we stay involved — supporting you with optimization, updates, and future improvements.
Contact with us
We’re open to collaboration and research partnerships. Fill out the form — our team will respond as soon as possible.
Location:
Europejski Instytut Biomedyczny sp. z o.o.
ul. Bartycka 63A lok. 6, 00-716 Warszawa
Mail:
contact@ebi.bio
Phone:
+48 22 780 06 32
Get in touch
